Weil Advises Sanofi in its $1.9B Acquisition of Kadmon Holdings, Inc.

Weil is advising Sanofi in its $1.9 billion acquisition of Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops and markets transformative therapies for disease areas of significant unmet medical needs. The transaction is expected to close in the fourth quarter of 2021, subject to customary closing conditions.

The Weil team advising Sanofi is led by Mergers & Acquisitions partner Michael J. Aiello and includes Mergers & Acquisitions partner Eoghan Keenan and Mergers & Acquisitions associates Kimberly ThibaultMichael Block and James Collins (Not Yet Admitted in New York). The team also includes Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions/Privacy associates Robert BrownLauren SpringerMaryann ThompsonMirish Shah and Alex Theuer (Not Yet Admitted in New York); Tax Head Joseph Pari; Tax partner Graham Magill; Tax associate Adam Romig (Not Yet Admitted in Washington, D.C.); Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits associates Manleen Singh (Admitted in Illinois Only) and Joshua Ehrhart (Not Yet Admitted in New York); Capital Markets partner Faiza Rahman; Structured Finance & Derivatives partner Ariel Kronman; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; and Antitrust associate Vivian Wang.